✦ LIBER ✦

Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer

✍ Scribed by Stephenson, Joe J.; Nemunaitis, John; Joy, Anil A.; Martin, Julie C.; Jou, Ying-Ming; Zhang, Da; Statkevich, Paul; Yao, Siu-Long; Zhu, Yali; Zhou, Honghong; Small, Karen; Bannerji, Rajat; Edelman, Martin J.

Book ID: 121525004
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 579 KB
Volume: 83
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2013.11.020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized Phase II Trial of the Cyclin-

Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer

✍ Mita, Monica M.; Joy, Anil A.; Mita, Alain; Sankhala, Kamalesh; Jou, Ying-Ming; 📂 Article 📅 2014 🏛 CIG Media Group, LP. 🌐 English ⚖ 369 KB

A randomized phase II study comparing er

A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study

✍ Aerts, J. G.; Codrington, H.; Lankheet, N. A. G.; Burgers, S.; Biesma, B.; Dinge 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 315 KB

Randomized phase II study of gefitinib v

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy

✍ Kim, Seung Tae; Uhm, Ji Eun; Lee, Jeeyun; Sun, Jong-mu; Sohn, Insuk; Kim, Seon W 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 359 KB

Characterization of skin pathology in no

Characterization of skin pathology in non–small cell lung cancer patients treated with the EGFR tyrosine kinase inhibitor erlotinib

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Pemetrexed versus erlotinib in pretreate

Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study

✍ Karampeazis, Athanasios; Voutsina, Alexandra; Souglakos, John; Kentepozidis, Nik 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 399 KB

Randomized Phase III Trial of Erlotinib

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

✍ Kawaguchi, T.; Ando, M.; Asami, K.; Okano, Y.; Fukuda, M.; Nakagawa, H.; Ibata, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 183 KB